ATE310517T1 - Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit - Google Patents
Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheitInfo
- Publication number
- ATE310517T1 ATE310517T1 AT99919772T AT99919772T ATE310517T1 AT E310517 T1 ATE310517 T1 AT E310517T1 AT 99919772 T AT99919772 T AT 99919772T AT 99919772 T AT99919772 T AT 99919772T AT E310517 T1 ATE310517 T1 AT E310517T1
- Authority
- AT
- Austria
- Prior art keywords
- cabergoline
- pramipexole
- treatment
- disease
- nervous system
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8561998P | 1998-05-15 | 1998-05-15 | |
US8794398P | 1998-06-04 | 1998-06-04 | |
PCT/US1999/007024 WO1999059563A2 (en) | 1998-05-15 | 1999-05-07 | Cabergoline and pramipexole for treating cns diseases, especially parkinson's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE310517T1 true ATE310517T1 (de) | 2005-12-15 |
Family
ID=26772918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99919772T ATE310517T1 (de) | 1998-05-15 | 1999-05-07 | Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit |
Country Status (22)
Country | Link |
---|---|
US (1) | US6503920B1 (de) |
EP (1) | EP1076559B1 (de) |
JP (1) | JP2002515425A (de) |
KR (3) | KR20010043612A (de) |
CN (1) | CN1301159A (de) |
AT (1) | ATE310517T1 (de) |
AU (1) | AU748629B2 (de) |
BR (1) | BR9909917A (de) |
CA (1) | CA2327299A1 (de) |
DE (1) | DE69928521T2 (de) |
DK (1) | DK1076559T3 (de) |
EA (4) | EA004474B1 (de) |
ES (1) | ES2251191T3 (de) |
HU (1) | HUP0101803A3 (de) |
IL (1) | IL139682A0 (de) |
NO (1) | NO20005757L (de) |
NZ (2) | NZ508184A (de) |
PL (1) | PL344574A1 (de) |
SG (1) | SG121745A1 (de) |
SK (1) | SK16272000A3 (de) |
TR (1) | TR200003356T2 (de) |
WO (1) | WO1999059563A2 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0007309D0 (en) * | 2000-03-24 | 2000-05-17 | Pharmacia & Upjohn Spa | Crystalline form V|| of cabergoline |
DE10053397A1 (de) | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
DE10138275A1 (de) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Verbindungen zur Beseitigung der Anhedonie |
DE10148233A1 (de) * | 2001-09-28 | 2003-04-10 | Boehringer Ingelheim Pharma | Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme |
PA8578501A1 (es) | 2002-07-25 | 2005-02-04 | Pharmacia Corp | Forma de dosificacion una vez al dia de pramipexol |
GB0221513D0 (en) | 2002-09-17 | 2002-10-23 | Generics Uk Ltd | Novel compounds and processes |
SG164375A1 (en) | 2004-08-13 | 2010-09-29 | Boehringer Ingelheim Int | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
EA201001083A1 (ru) | 2004-08-13 | 2011-08-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Композиция таблетки пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение |
US20090041844A1 (en) * | 2006-02-10 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Modified Release Formulation |
PL232974B1 (pl) * | 2015-12-09 | 2019-08-30 | Ofta Spolka Z Ograniczona Odpowiedzialnoscia | Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
DE3937271A1 (de) * | 1989-11-09 | 1991-05-16 | Boehringer Ingelheim Kg | Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol |
WO1995005176A1 (en) * | 1993-08-18 | 1995-02-23 | Alcon Laboratories, Inc. | Use of ergoline derivatives for the treatment of glaucoma |
US5496836A (en) * | 1994-05-05 | 1996-03-05 | Mount Sinai School Of Medicine Of The City University Of New York | Use of famotidine and related compounds in the treatment of movement disorders |
FR2728374A1 (fr) * | 1994-12-15 | 1996-06-21 | Aerospatiale | Procede et dispositif pour fournir une information, alerte ou alarme pour un aeronef a proximite du sol |
US5650420A (en) * | 1994-12-15 | 1997-07-22 | Pharmacia & Upjohn Company | Pramipexole as a neuroprotective agent |
-
1999
- 1999-05-07 EA EA200001192A patent/EA004474B1/ru not_active IP Right Cessation
- 1999-05-07 BR BR9909917-9A patent/BR9909917A/pt not_active Application Discontinuation
- 1999-05-07 NZ NZ508184A patent/NZ508184A/en unknown
- 1999-05-07 WO PCT/US1999/007024 patent/WO1999059563A2/en active IP Right Grant
- 1999-05-07 CA CA002327299A patent/CA2327299A1/en not_active Abandoned
- 1999-05-07 EA EA200300125A patent/EA200300125A1/ru unknown
- 1999-05-07 DE DE69928521T patent/DE69928521T2/de not_active Expired - Fee Related
- 1999-05-07 SG SG200206791A patent/SG121745A1/en unknown
- 1999-05-07 JP JP2000549228A patent/JP2002515425A/ja active Pending
- 1999-05-07 KR KR1020007012760A patent/KR20010043612A/ko not_active Application Discontinuation
- 1999-05-07 CN CN99805219A patent/CN1301159A/zh active Pending
- 1999-05-07 PL PL99344574A patent/PL344574A1/xx not_active IP Right Cessation
- 1999-05-07 IL IL13968299A patent/IL139682A0/xx unknown
- 1999-05-07 US US09/674,838 patent/US6503920B1/en not_active Expired - Fee Related
- 1999-05-07 AU AU37419/99A patent/AU748629B2/en not_active Ceased
- 1999-05-07 KR KR1020067007720A patent/KR20060056417A/ko not_active Application Discontinuation
- 1999-05-07 NZ NZ526071A patent/NZ526071A/en unknown
- 1999-05-07 KR KR1020067007719A patent/KR20060056416A/ko not_active Application Discontinuation
- 1999-05-07 AT AT99919772T patent/ATE310517T1/de not_active IP Right Cessation
- 1999-05-07 SK SK1627-2000A patent/SK16272000A3/sk unknown
- 1999-05-07 HU HU0101803A patent/HUP0101803A3/hu unknown
- 1999-05-07 EA EA200200955A patent/EA200200955A1/ru unknown
- 1999-05-07 DK DK99919772T patent/DK1076559T3/da active
- 1999-05-07 ES ES99919772T patent/ES2251191T3/es not_active Expired - Lifetime
- 1999-05-07 TR TR2000/03356T patent/TR200003356T2/xx unknown
- 1999-05-07 EA EA200300124A patent/EA200300124A1/ru unknown
- 1999-05-07 EP EP99919772A patent/EP1076559B1/de not_active Expired - Lifetime
-
2000
- 2000-11-14 NO NO20005757A patent/NO20005757L/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
DE69815122D1 (de) | Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen | |
DE60236413D1 (de) | Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten | |
WO2002002518A3 (en) | Compounds to treat alzheimer's disease | |
WO2002002520A8 (en) | Compounds to treat alzheimer's disease | |
AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
DK1632483T3 (da) | Heterocykliske, substituerede carbonylderivater og deres anvendelse som dopamin-D3-receptorligander | |
DE69939705D1 (de) | Behandlung der pompeschen krankheit | |
ATE310517T1 (de) | Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit | |
ATE386520T1 (de) | Kombination von riluzol und levodopa zur behandlung von morbus parkinson | |
DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
SE0102147D0 (sv) | New methods | |
ATE366581T1 (de) | Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen | |
DK1392676T3 (da) | Hidtil ukendte heterocykliske urinstofderivater og deres anvendelse som dopamin -D3 - receptorligander | |
HUP0001913A2 (hu) | Pramipexole alkalmazása állandóan mozgó láb szindróma kezelésére szolgáló gyógyszerkészítmények előállítására | |
MY124071A (en) | Treatment of viral disease in swine | |
HUP0300566A2 (hu) | Galantamin alkalmazása az Alzheimer-kórral összefüggő neuropszichiátriai viselkedésformák terápiájában | |
BR0311180A (pt) | Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos | |
DE3865283D1 (de) | Butylhydroxyanisole zur behandlung von retrovirus-krankheiten. | |
ATE288263T1 (de) | Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis) | |
PT1304107E (pt) | Utilizacao de derivados de oxazolidininas para o tratamento da psoriase | |
MX9503363A (es) | N-(2,6-dioxo-3-piperidil) ftalimida (generico talidomida como tratamiento del sindrome de desgaste asociado con la infeccion por vih-1. | |
BR0015486A (pt) | Ligandos de neurofilina para tratamento de condições oculares | |
EA199800737A1 (ru) | Способ лечения заболеваний, связанных с образованием конкрементов | |
UA42274A (uk) | Спосіб профілактики та лікування функціональних розладів організму пацієнта |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1076559 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |